ASTX727 not checked

Taiho

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 2 trial completes
Trials
9 active
11 in total · 9 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“subjects will receive treatment with ASTX727, 1 tablet/day for 5 consecutive days, in 28-day cycles, until disease progression, unacceptable toxicity, or the subject/investigator decides that the subject should discontinue treatment or withdraw from the trial.”In the company’s words, NCT06091267 on ClinicalTrials.gov
Tested for
Myelodysplastic Syndromes (5 trials), Acute Myeloid Leukemia (4 trials), Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Patient Preference, Chronic Myelomonocytic Leukemia
Main trialPhase 3
“It is hypothesized that significantly more patients would prefer oral decitabine/cedazuridine to subcutaneous (SC) azacitidine (AZA) due to several factors, including improved treatment convenience, the reduced risk of nosocomial infections, and reduced treatment discomfort. However, this hypothesis has not been formally studied in a controlled setting. This study aims to address this evidence gap and evaluate patient, primary caregiver (carer), and clinician treatment preference between oral decitabine/cedazuridine and SC AZA in the treatment of adult patients with International Prognostic…”In the company’s words, NCT05883956 on ClinicalTrials.gov
Other names
cedazuridine + decitabine · INQOVI · DEC-C · Oral decitabine and cedazuridine · Decitabine and Cedazuridine · decitabine/cedazuridine

Other drugs for Myelodysplastic Syndromes

All 96 drugs for Myelodysplastic Syndromes

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials11

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 6 Dec 2024 A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia
Phase 2Enrolling by invitation 31 Dec 2027 A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Phase 1/2Active, not recruiting 30 Sep 2024 Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)
Phase 1/2Active, not recruiting 22 May 2026 PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes
Phase 1Recruiting Dec 2026 Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
Phase 1Recruiting Dec 2026 Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
Phase 1/2Completed 13 Jan 2026 Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS
Phase 2Authorised not given PHASE II STUDY OF AZACITIDINE IN COMBINATION WITH LOW DOSE INTENSITY VENETOCLAX IN PATIENTS WITH ACUTE MYELOID LEUKEMIA WITH INTEGRATION OF EXPLORATIVE MULTI-OMICS AND EX VIVO DRUG SCREENING DATA
Phase 2Ended not given GFM-DACORAL-DLI: ASTX727 and donor lymphocyte infusions (DLI) after allogeneic stem cell transplantation (ALLO SCT) in very high-risk MDS or AML patients
Phase 2Authorised not given A randomized, run-in, phase II study of nivolumab combined with ipilimumab and oral decitabine/cedazuridine (ASTX727) or nivolumab combined with ipilimumab in melanoma and NSCLC patients resistant to anti-PD-1/PD-L1
Phase 2Authorised not given A phase II, multicentre, open label clinical trial evaluating the efficacy and safety of oral decitabine plus ivosidenib in adult patients with newly diagnosed acute myeloid leukemia older than 60 years old and/or who are ineligible for standard induction chemotherapy
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow ASTX727

Following is part of Solo: you see every change to ASTX727 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in